Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Narrative reviews on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Histopathology, Immunohistochemistry, Clinical Proteomics, Derivative Assay, Genetically Modified, Activity Assay, Generated

Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Published clinical trials on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Clinical Proteomics, Control, Transplantation Assay, Infection

Journal: Clinics

Article Title: Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review

doi: 10.1016/j.clinsp.2023.100237

Figure Lengend Snippet: Unpublished clinical trials on the administration of ASCs in chronic or acute lung diseases.

Article Snippet: Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020) , • Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities , • 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative) , • Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days , • Three doses of placebo via intravenously infusion every three days. , • Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] , Not yet recruiting.

Techniques: Clinical Proteomics, Derivative Assay, Biomarker Discovery, Isolation, Saline, Transplantation Assay, Concentration Assay, Functional Assay, Control, Infection, Reverse Transcription Polymerase Chain Reaction, Activity Assay, Comparison, Injection, Computed Tomography, Sterility, Coagulation

Journal: Cell and Tissue Banking

Article Title: The promising approach of MSCs therapy for COVID-19 treatment

doi: 10.1007/s10561-022-10060-2

Figure Lengend Snippet: Summarized clinical trial (marked “completed”) studies on the MSCs in the COVID-19 ( https://www.clinicaltrials.gov )

Article Snippet: NCT04522986 , An exploratory study of ADR-001 in patients with severe pneumonia caused by SARS-CoV-2 infection , Rohto Pharmaceutical Co., Ltd./ Japan , 6 , MSC 1 × 10 ^ 8 cells were administered once a week, total four times intravenously. , I , Patients with Severe Pneumonia caused by SARS-CoV-2 infection were enrolled to the study. adMSCs were administered once a week, total four times intravenously. Safety and efficacy of adMSCs were evaluated for 12 weeks after first administer..

Techniques: Injection, Marker, Real-time Polymerase Chain Reaction, Transplantation Assay, Infection, Saline, Modification, Ex Vivo, Derivative Assay, Clinical Proteomics, Control, Virus, Flow Cytometry